Lawrence D. Kingsley - 06 May 2024 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
08 May 2024, 19:02:14 UTC
Prior SEC filing
29 Apr 2024
Next SEC filing
04 Jun 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Lily J. Lu, Attorney-in-Fact for Lawrence D. Kingsley

Key filing fact

Lawrence D. Kingsley filed Form 4 for IDEXX LABORATORIES INC /DE (IDXX) on 08 May 2024.

Key facts

  • This page summarizes Lawrence D. Kingsley's Form 4 filing for IDEXX LABORATORIES INC /DE (IDXX).
  • 8 reported transactions and 6 derivative rows are listed below.
  • Accepted by SEC: 08 May 2024, 19:02.

Change

  • Previous filing in this sequence was filed on 29 Apr 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IDXX transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+257
Change %
+3%
Price
$0.000000
Shares after
8,801
Date
06 May 2024
Ownership
Direct
IDXX transaction

Common Stock

Options Exercise

Transaction value
$0
Shares
+82
Change %
+0.93%
Price
$0.000000
Shares after
8,883
Date
06 May 2024
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IDXX transaction Derivative

Non-Qualified Stock Option (right-to-buy)

Award

Transaction value
$0
Shares
+609
Change %
Price
$0.000000
Shares after
609
Date
06 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
609
Exercise price
$476.87
Footnotes
F1
IDXX transaction Derivative

Non-Qualified Stock Option (right-to-buy)

Award

Transaction value
$0
Shares
+195
Change %
Price
$0.000000
Shares after
195
Date
06 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
195
Exercise price
$476.87
Footnotes
F1, F2
IDXX transaction Derivative

Restricted Stock Unit

Award

Transaction value
$0
Shares
+262
Change %
Price
$0.000000
Shares after
262
Date
06 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
262
Exercise price
Footnotes
F3
IDXX transaction Derivative

Restricted Stock Unit

Award

Transaction value
$0
Shares
+84
Change %
Price
$0.000000
Shares after
84
Date
06 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
84
Exercise price
Footnotes
F2, F3
IDXX transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
$0
Shares
-257
Change %
-100%
Price
$0.000000*
Shares after
0
Date
06 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
257
Exercise price
Footnotes
F4
IDXX transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
$0
Shares
-82
Change %
-100%
Price
$0.000000*
Shares after
0
Date
06 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
82
Exercise price
Footnotes
F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

Footnote F2

Additional grant made as Independent Non-Executive Board Chair.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier.

Footnote F4

Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .